Policy & Regulation
ImmunoPrecise subsidiary Talem forms research collaboration with Astellas
30 March 2023 -

ImmunoPrecise Antibodies Ltd (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, said on Thursday that its subsidiary Talem has entered into a research collaboration and exclusive option licence agreement with Xyphos Biosciences Inc, a subsidiary of Japanese pharmaceutical company Astellas Pharma Inc (Tokyo:4503).

Under this agreement the two companies will jointly conduct research activities to identify and optimise proprietary LENSai in silico generated antibodies, targeting an undisclosed target in the tumour microenvironment (TME), as potential therapeutic development candidates.

Targeting this molecule in the TME has the potential to markedly enhance anti-tumour immunity with other Astellas therapies including chimeric antigen receptor-based (CAR) technologies, ImmunoPrecise said.

Astellas will have the exclusive option to license any development candidates generated as part of the collaboration.

Login
Username:

Password: